Form 4: Apellis VP Sells Shares for Tax Withholding

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 189 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• James Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction involving the company's common stock.
• On September 15, 2025, Chopas sold 189 shares of Apellis common stock at a price of $24.192 per share.
• The sale was executed to cover tax withholding obligations associated with Restricted Stock Units (RSUs) that vested on September 12, 2025.
• Following this transaction, Chopas beneficially owns 53,468 shares of Apellis common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-arranged sale.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax withholding on vested equity, indicating a neutral sentiment regarding the company's prospects.

Positives

• Restricted Stock Units (RSUs) held by the VP/Chief Accounting Officer vested, representing a positive compensation event for the executive.

Future Outlook

This Form 4 filing, detailing a routine insider transaction for tax purposes, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries when executive compensation includes equity awards. It does not reflect specific industry trends or competitive dynamics.

Comparison to Industry Standards

• The sale of shares to cover tax withholding on vested equity awards is a common practice for executives across all industries and is considered a standard, non-discretionary transaction.

Stakeholder Impact

• Shareholders: The sale of 189 shares represents a negligible amount relative to Apellis Pharmaceuticals' total outstanding shares, resulting in minimal to no impact on share price or ownership structure.
• Employees: No direct impact on the broader employee base is indicated by this routine executive compensation-related transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of a small number of shares by a company officer to cover tax withholding on vested equity. Such transactions are common and do not typically indicate a change in the officer's outlook on the company's fundamentals or future performance. Therefore, it provides no new information to warrant a change from a 'hold' recommendation.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, insider transaction, stock sale, tax withholding, RSU, James Chopas, Chief Accounting Officer